SV

Street Verdict

Analyst Scorecard

A record of what Emkay Global Financial Services Analysis said publicly, with the source. Not advice.

“Emkay retained a 'BUY' rating on Sun Pharma with a target price of ₹2,000, reflecting a positive outlook on the company's long-term prospects, driven by its speciality pipeline and growth initiatives.”

Emkay Global Financial Services Analysis’s track record (trackable calls only): 179 graded calls · 95% CI 47–61%

Sun Pharmaceutical IndustriesBullishCalled 10 Nov 2025Graded 30 Jul 2026
Verdict:HIT

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹2,000, as stated.

Window: 12 months, the default when no time frame is stated.

The target ₹2,000 was reached on a close. Hit.

The grader’s working: R4 TARGET_CALL: entered ₹1716.1 on 2025-11-11 (next trading session's close); target ₹2000 reached at close ₹2001.1 on 2026-07-30. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.

How it played out

How this is worked out
Time to target
The target was reached on a close 176 trading sessions (261 calendar days) after the entry.
Worst close against it
The closing price went as far as 7.39% against the call before the target was reached, measured from the entry price. Closing prices only; an intraday dip is never counted.

From the entry the grade used, on closing prices. This is a record of one past call and is not advice.

Tracking Sun Pharmaceutical Industries since this call

1-year tracking window
Read the original articleSee Emkay Global Financial Services Analysis’s full track record